Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Equity Average (2022 - 2025)

Historic Equity Average for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $3.4 million.

  • bioAffinity Technologies' Equity Average rose 323.38% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 323.38%. This contributed to the annual value of $3.7 million for FY2024, which is 5309.5% down from last year.
  • Latest data reveals that bioAffinity Technologies reported Equity Average of $3.4 million as of Q3 2025, which was up 323.38% from -$348352.0 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Equity Average ranged from a high of $11.8 million in Q4 2022 and a low of -$348352.0 during Q2 2025
  • Moreover, its 4-year median value for Equity Average was $4.7 million (2024), whereas its average is $5.4 million.
  • Examining YoY changes over the last 5 years, bioAffinity Technologies' Equity Average showed a top increase of 323.38% in 2025 and a maximum decrease of 10801.72% in 2025.
  • bioAffinity Technologies' Equity Average (Quarter) stood at $11.8 million in 2022, then tumbled by 49.88% to $5.9 million in 2023, then crashed by 51.7% to $2.9 million in 2024, then rose by 18.23% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, -$348352.0 for Q2 2025, and $2.0 million during Q1 2025.